DE602006017331D1 - Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien - Google Patents

Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Info

Publication number
DE602006017331D1
DE602006017331D1 DE602006017331T DE602006017331T DE602006017331D1 DE 602006017331 D1 DE602006017331 D1 DE 602006017331D1 DE 602006017331 T DE602006017331 T DE 602006017331T DE 602006017331 T DE602006017331 T DE 602006017331T DE 602006017331 D1 DE602006017331 D1 DE 602006017331D1
Authority
DE
Germany
Prior art keywords
biologically active
bacteria
darm
supply
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017331T
Other languages
English (en)
Inventor
Simon Carding
Mark Farrar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plant Bioscience Ltd
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Publication of DE602006017331D1 publication Critical patent/DE602006017331D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006017331T 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien Active DE602006017331D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (1)

Publication Number Publication Date
DE602006017331D1 true DE602006017331D1 (de) 2010-11-18

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017331T Active DE602006017331D1 (de) 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Country Status (10)

Country Link
US (1) US7988961B2 (de)
EP (1) EP1841875B1 (de)
JP (1) JP4989490B2 (de)
KR (1) KR101291960B1 (de)
AT (1) ATE483811T1 (de)
CA (1) CA2640343C (de)
DE (1) DE602006017331D1 (de)
ES (1) ES2353721T3 (de)
GB (1) GB0501540D0 (de)
WO (1) WO2006079790A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055362A1 (en) * 2007-10-26 2009-04-30 Moore Brenda E Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (de) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumorspezifische bakterielle Promoterelemente
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
US10047405B2 (en) 2013-12-20 2018-08-14 President And Fellows Of Harvard College Engineered genetic enteric sensor bacteria and uses thereof
WO2016141108A1 (en) * 2015-03-02 2016-09-09 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
PL3377518T3 (pl) 2015-11-16 2022-09-26 Synlogic Operating Company, Inc. Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
WO2017184565A1 (en) * 2016-04-20 2017-10-26 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
EP3554518A4 (de) 2016-12-15 2020-07-29 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur modulation des wachstums einer genetisch modifizierten darmbakterienzelle
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
US20200268813A1 (en) * 2017-02-15 2020-08-27 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
WO2021188819A1 (en) 2020-03-20 2021-09-23 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (de) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative Genexpression in Streptococcus sulivarius ssp. thermophilus
CA2382067A1 (en) * 1999-09-10 2001-03-22 The Secretary Of State For Defence Recombinant microorganisms
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−１，３−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−１，３−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
CA2640343C (en) 2014-01-14
KR20070108882A (ko) 2007-11-13
US7988961B2 (en) 2011-08-02
KR101291960B1 (ko) 2013-08-09
CA2640343A1 (en) 2006-08-03
JP2008527988A (ja) 2008-07-31
ATE483811T1 (de) 2010-10-15
EP1841875B1 (de) 2010-10-06
GB0501540D0 (en) 2005-03-02
JP4989490B2 (ja) 2012-08-01
ES2353721T3 (es) 2011-03-04
US20080131402A1 (en) 2008-06-05
WO2006079790A3 (en) 2006-12-21
EP1841875A2 (de) 2007-10-10
WO2006079790A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
DE602006017331D1 (de) Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
ES2486675T3 (es) Análogo de péptido de oxintomodulina
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
NL301089I2 (nl) imlifidase
GB0514779D0 (en) Biological products
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
ES2585185T3 (es) Polipéptidos quiméricos y sus aplicaciones terapéuticas contra una infección por Flaviviridae
NZ629649A (en) Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
PE20130593A1 (es) DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
BR112013010487A2 (pt) novos substratos de coelenterazina e métodos de uso
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
NZ596037A (en) Fgf21 mutants and uses thereof
MX2009013137A (es) Metodos para seleccionar polipeptidos resistentes a la proteasa.
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
DE602007006492D1 (de) Derivatisierung des granulozytenkoloniestimulierenden faktors
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
PE20120551A1 (es) Anticuerpos contra la angiopoyetina 2 humana
NZ596658A (en) Dig-10 insecticidal cry toxins
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
AR053259A1 (es) Trigo con nuevo almidon y metodo para producirlo
ES2531480T3 (es) Péptidos derivados de la proteína bplp humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
EP2195331A4 (de) Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PLANT BIOSCIENCE LTD., NORWICH, NORFOLK, GB

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE FREISCHEM, 50677 KOELN